The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Pneumonitis (ILD)
Publications
Pulmonary disorders induced by monoclonal antibodies in patients with rheumatologic autoimmune diseases.
The American journal of medicine 2011 May;124;386-94 — 2011 May — 386-94
Perez-Alvarez R, Perez-de-Lis M, Diaz-Lagares C, Pego-Reigosa JM, Retamozo S, Bove A, Brito-Zeron P, Bosch X, Ramos-Casals M
Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases.
Seminars in arthritis and rheumatism 2011 Oct;41;256-64 — 2011 Oct — 256-64
Pulmonary complications of tumor necrosis factor-targeted therapy.
Respiratory medicine 2009 May;103;661-9 — 2009 May — 661-9
Exacerbation of interstitial lung disease during etanercept therapy: Two cases.
Joint, bone, spine : revue du rhumatisme 2008 Mar;75;215-8 — 2008 Mar — 215-8
Pulmonary lymphohistiocytic reactions temporally related to etanercept therapy.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2005 May;18;651-5 — 2005 May — 651-5
Lung injury linked to etanercept therapy.
Chest 2002 Nov;122;1858-60 — 2002 Nov — 1858-60